A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

NCT02791516 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: Romosozumab
DRUG: Placebo

Sponsor

Amgen